Lumos Pharma, Inc. (LUMO) Research

Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic compound, LUM-201, an orally administered growth hormone secretagogue called ibutamoren, is currently undergoing Phase 2 clinical evaluation. This drug candidate is being investigated for its potential in treating pediatric growth hormone deficiency and various other uncommon endocrine conditions. The company's operations are based in Austin, Texas.

Market snapshot

Symbol
LUMO
Price
$4.34
Day change
0.00%
Market cap
$37.5M
P/E ratio
-1.04x
52-week range
1.3701-4.5756
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$16.50

Peer companies

  • Cerecor Inc. (CERC)
  • Eyenovia, Inc. (EYEN)
  • Grace Therapeutics, Inc. (GRCE)
  • Opus Genetics, Inc. (IRD)
  • LianBio (LIANY)
  • Magenta Therapeutics, Inc. (MGTA)
  • Oruka Therapeutics, Inc. (ORKA)
  • Pluristem Therapeutics Inc. (PSTI)

Recent insider activity

  • Pitukcheewanont Pisit Duke — trade (0 shares) on 2024-01-04
  • Pitukcheewanont Pisit Duke — trade (3333 shares) on 2024-02-01
  • Pitukcheewanont Pisit Duke — trade (25500 shares) on 2024-07-01
  • Pitukcheewanont Pisit Duke — trade (29750 shares) on 2023-06-01
  • McKew John C. — F-InKind (1593 shares) on 2023-08-01

Open Lumos Pharma, Inc. (LUMO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.